Key facts
- Notable investors include MassChallenge, Austria Wirtschaftsservice, FS Life Science Investment, VGW Beteiligungs, VP Venture Partners — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Diamens
- ·The full record, as it builds
Funding rounds
No funding rounds for Diamens are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Diamens
Developer of a diagnostic testing platform designed to detect female-specific conditions through non-invasive sampling methods. The company provides menstrual blood self-sampling kits combined with laboratory analysis and biomarker-based models to support the diagnosis of conditions such as endometriosis, enabling patients and healthcare providers to access earlier, more accessible, and data-driven diagnostic insights.
- Sector
- Healthcare
- HQ
- Linz, Austria
- Founded
- 2022
- Employees
- 4
- Website
- diamens.org/
- Ownership
- Privately Held (backing)
Diamens doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Diamens shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Diamens in its N-PORT filings yet. We sweep new filings monthly.